| Primary |
| Plasma Cell Myeloma |
59.5% |
| Multiple Myeloma |
16.9% |
| Waldenstrom's Macroglobulinaemia |
3.8% |
| Product Used For Unknown Indication |
2.5% |
| Acute Myeloid Leukaemia |
2.1% |
| Premedication |
2.1% |
| Hypertension |
1.7% |
| Mineral Supplementation |
1.7% |
| Prophylaxis |
1.7% |
| Insomnia |
1.3% |
| Myocardial Ischaemia |
1.3% |
| Anxiety |
0.8% |
| Hiatus Hernia |
0.8% |
| Pain Management |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
| Acute Myeloid Leukemia Recurrent |
0.4% |
| Acromegaly |
0.4% |
| Amyloidosis |
0.4% |
| Antibiotic Prophylaxis |
0.4% |
| Antiviral Prophylaxis |
0.4% |
|
| Thrombocytopenia |
10.6% |
| Vomiting |
10.6% |
| Thrombotic Thrombocytopenic Purpura |
8.5% |
| Dyspnoea |
6.4% |
| Pulmonary Embolism |
6.4% |
| Tachycardia |
6.4% |
| Urinary Tract Infection |
6.4% |
| Disease Progression |
4.3% |
| Plasma Cell Myeloma |
4.3% |
| Pulmonary Congestion |
4.3% |
| Pulmonary Hypertension |
4.3% |
| Pyrexia |
4.3% |
| Sepsis |
4.3% |
| Unresponsive To Stimuli |
4.3% |
| Ventricular Hypokinesia |
4.3% |
| Affective Disorder |
2.1% |
| Arrhythmia |
2.1% |
| Atelectasis |
2.1% |
| Cardio-respiratory Distress |
2.1% |
| Cardiopulmonary Failure |
2.1% |
|
| Secondary |
| Multiple Myeloma |
20.0% |
| Plasma Cell Myeloma |
12.8% |
| Prophylaxis |
9.5% |
| Antiviral Prophylaxis |
8.4% |
| Hypertension |
7.3% |
| Anticoagulant Therapy |
7.0% |
| Product Used For Unknown Indication |
6.1% |
| Antibiotic Prophylaxis |
6.1% |
| Antiplatelet Therapy |
3.9% |
| Anxiety |
2.5% |
| Constipation |
2.5% |
| Supplementation Therapy |
2.2% |
| Depression |
2.0% |
| Abdominal Pain |
2.0% |
| Nausea |
1.7% |
| Pain |
1.4% |
| Bone Pain |
1.2% |
| Plasma Cell Myeloma Recurrent |
1.2% |
| Type 2 Diabetes Mellitus |
1.0% |
| Myeloma Recurrence |
0.9% |
|
| Hepatitis C |
10.3% |
| Colitis |
9.4% |
| Acute Myeloid Leukaemia |
9.0% |
| Death |
6.3% |
| Myelodysplastic Syndrome |
6.3% |
| Myocardial Infarction |
6.3% |
| Cerebrovascular Accident |
5.4% |
| Hypocalcaemia |
5.4% |
| Brain Mass |
4.9% |
| Plasmacytoma |
4.9% |
| Adenocarcinoma Of Colon |
4.0% |
| Paraparesis |
3.6% |
| Pneumonia |
3.6% |
| Pyrexia |
3.6% |
| Cardiac Arrest |
3.1% |
| Respiratory Tract Infection |
3.1% |
| Altered State Of Consciousness |
2.7% |
| Chronic Hepatitis C |
2.7% |
| Electrolyte Imbalance |
2.7% |
| Ischaemic Stroke |
2.7% |
|
| Concomitant |
| Product Used For Unknown Indication |
53.6% |
| Plasma Cell Myeloma |
12.8% |
| Multiple Myeloma |
12.3% |
| Drug Use For Unknown Indication |
9.8% |
| Pain |
1.9% |
| Acute Myeloid Leukaemia |
0.8% |
| Deep Vein Thrombosis |
0.8% |
| Diarrhoea |
0.8% |
| Osteomyelitis |
0.8% |
| Pyrexia |
0.8% |
| Abscess Fungal |
0.5% |
| Anti-infective Therapy |
0.5% |
| Antiviral Prophylaxis |
0.5% |
| Constipation |
0.5% |
| Diabetes Mellitus |
0.5% |
| Haematopoietic Stem Cell Mobilisation |
0.5% |
| Haemoglobin Decreased |
0.5% |
| Hepatitis B |
0.5% |
| Hepatitis C |
0.5% |
| Mucosal Inflammation |
0.5% |
|
| Plasma Cell Myeloma |
16.7% |
| Prostate Cancer Metastatic |
13.9% |
| Dysphagia |
5.6% |
| Polyneuropathy |
5.6% |
| Renal Failure |
5.6% |
| Staphylococcal Bacteraemia |
5.6% |
| Thrombosis |
5.6% |
| Tooth Loss |
5.6% |
| Toxicity To Various Agents |
5.6% |
| Acute Myeloid Leukaemia |
2.8% |
| Cerebrovascular Accident |
2.8% |
| Lip Swelling |
2.8% |
| Melanocytic Naevus |
2.8% |
| Meningomyelocele |
2.8% |
| Oedema Peripheral |
2.8% |
| Pneumonia |
2.8% |
| Pulmonary Embolism |
2.8% |
| Renal Failure Acute |
2.8% |
| Sinus Bradycardia |
2.8% |
| Therapeutic Response Unexpected |
2.8% |
|
